{"id":55066,"date":"2025-07-30T08:38:13","date_gmt":"2025-07-30T08:38:13","guid":{"rendered":"https:\/\/ibima.eu\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/"},"modified":"2025-07-30T08:38:13","modified_gmt":"2025-07-30T08:38:13","slug":"a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/","title":{"rendered":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event \u2013 ACCLAIM-Lp(a)"},"content":{"rendered":"<p>FRANCISCO JOS\u00c9 TINAHONES MADUE\u00d1O &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; LILLY, S.A.<\/p>","protected":false},"excerpt":{"rendered":"<p>FRANCISCO JOS\u00c9 TINAHONES MADUE\u00d1O &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; LILLY, S.A.<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2266],"tags":[],"class_list":["post-55066","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-a-02-ensayos-clinicos"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event \u2013 ACCLAIM-Lp(a) - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event \u2013 ACCLAIM-Lp(a) - Ibima\" \/>\n<meta property=\"og:description\" content=\"FRANCISCO JOS\u00c9 TINAHONES MADUE\u00d1O &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; LILLY, S.A.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:38:13+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event \u2013 ACCLAIM-Lp(a)\",\"datePublished\":\"2025-07-30T08:38:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\\\/\"},\"wordCount\":59,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - A-02\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\\\/\",\"name\":\"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event \u2013 ACCLAIM-Lp(a) - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:38:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event \u2013 ACCLAIM-Lp(a)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/en\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event \u2013 ACCLAIM-Lp(a) - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/","og_locale":"en_GB","og_type":"article","og_title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event \u2013 ACCLAIM-Lp(a) - Ibima","og_description":"FRANCISCO JOS\u00c9 TINAHONES MADUE\u00d1O &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; LILLY, S.A.","og_url":"https:\/\/ibima.eu\/en\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:38:13+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event \u2013 ACCLAIM-Lp(a)","datePublished":"2025-07-30T08:38:13+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/"},"wordCount":59,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - A-02"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/","url":"https:\/\/ibima.eu\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/","name":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event \u2013 ACCLAIM-Lp(a) - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:38:13+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/a-phase-3-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-lepodisiran-on-the-reduction-of-major-adverse-cardiovascular-events-in-adults-with-elevated-lipoproteina-wh\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event \u2013 ACCLAIM-Lp(a)"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/en\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/55066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=55066"}],"version-history":[{"count":0,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/55066\/revisions"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=55066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/categories?post=55066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/tags?post=55066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}